These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1136 related items for PubMed ID: 18095227

  • 21. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT, Liao CH, Teng LJ, Hsueh PR.
    Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
    [Abstract] [Full Text] [Related]

  • 22. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study.
    Crank CW, Scheetz MH, Brielmaier B, Rose WE, Patel GP, Ritchie DJ, Segreti J.
    Clin Ther; 2010 Sep; 32(10):1713-9. PubMed ID: 21194593
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium.
    Abb J.
    Int J Antimicrob Agents; 2007 Mar; 29(3):358-60. PubMed ID: 17229553
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?
    Mave V, Garcia-Diaz J, Islam T, Hasbun R.
    J Antimicrob Chemother; 2009 Jul; 64(1):175-80. PubMed ID: 19423543
    [Abstract] [Full Text] [Related]

  • 31. [Infections with drug resistant bacteria and their treatment methods--VRE infections].
    Fujita N, Komori T.
    Rinsho Byori; 2000 Jan; Suppl 111():132-41. PubMed ID: 10804803
    [Abstract] [Full Text] [Related]

  • 32. Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid.
    Wareham DW, Abbas H, Karcher AM, Das SS.
    J Infect; 2006 Apr; 52(4):300-4. PubMed ID: 16099052
    [Abstract] [Full Text] [Related]

  • 33. Incidence and risk factors of vancomycin-resistant enterococcus colonization in burn unit patients.
    Altoparlak U, Koca O, Ozkurt Z, Akcay MN.
    Burns; 2011 Feb; 37(1):49-53. PubMed ID: 20926196
    [Abstract] [Full Text] [Related]

  • 34. Optimizing therapy for vancomycin-resistant enterococcal bacteremia in children.
    Tamma PD, Hsu AJ.
    Curr Opin Infect Dis; 2014 Dec; 27(6):517-27. PubMed ID: 25313503
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.
    Johnson AP, Mushtaq S, Warner M, Livermore DM.
    Int J Antimicrob Agents; 2004 Oct; 24(4):315-9. PubMed ID: 15380254
    [Abstract] [Full Text] [Related]

  • 37. Enterococcal resistance--an overview.
    Marothi YA, Agnihotri H, Dubey D.
    Indian J Med Microbiol; 2005 Oct; 23(4):214-9. PubMed ID: 16327115
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance.
    Segreti J.
    Clin Microbiol Infect; 2005 May; 11 Suppl 3():29-35. PubMed ID: 15811022
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Combination therapy against vancomycin-resistant enterococci].
    Kariyama R, Kumon H.
    Nihon Rinsho; 2001 Apr; 59(4):733-8. PubMed ID: 11304998
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 57.